rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SUPN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Does Supernus Pharmaceuticals (SUPN) Still Trade Below Fair Value On Sales?

      Supernus Pharmaceuticals has delivered a 75.7% gain over the past three years, even though the stock is down year to date, which naturally puts the current share price under the microscope. The immediate question for you as an investor is whether that price is still grounded in what the business is actually generating in sales. The 75.7% return over three years puts real weight on the question of whether Supernus Pharmaceuticals' current valuation can still be explained by its revenue...

      Nov 18Yahoo FinanceSUPN
      Supernus undervalued after Indivior merger, says Bank of America
      Nov 9Yahoo FinanceINDVSUPNBAC
      This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
      Nov 9BenzingaSUPN
      BofA initiates Supernus Pharmaceuticals stock at buy on merger scale
      Nov 9Investing.comSUPN
      Supernus resumed at overweight at Piper Sandler on Indivior merger
      Nov 4Seeking AlphaINDVSUPNPIPR
      Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued

      Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus Pharmaceuticals. The share price closed at $41.92 after a 7 day share price return of 2.34%, yet the 90 day share price return declined 10.64% and the 1 year total shareholder return fell 26.46%. However,...

      Nov 4Yahoo FinanceINDVSUPN
      Piper Sandler resumes Supernus Pharmaceuticals stock at Overweight
      Nov 4Investing.comSUPN
      What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?

      Supernus Pharmaceuticals (NasdaqGM:SUPN) has completed its merger of equals with Indivior Pharmaceuticals, forming a combined specialty pharma business. As part of the transaction, Supernus shares have been delisted from Nasdaq, with equity now rolling into the new merged entity. The deal includes consolidation of corporate structures and leadership roles, with governance now housed under a single combined board and executive team. The completion of the Supernus and Indivior merger and...

      Nov 3Yahoo FinanceSUPN
      Supernus adjusts convertible notes conversion rate following special dividend
      Nov 3Investing.comSUPN
      Why Indivior Pharmaceuticals Stock Topped the Market Today

      Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.

      Nov 2The Globe and MailSUPN
      Supernus Pharmaceuticals to delist shares from Nasdaq following merger
      Nov 2Investing.comSUPN
      Supernus Pharmaceuticals Completes Merger With Indivior Pharmaceuticals
      Nov 2Yahoo FinanceINDVSUPN
      Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

      Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipelineSignificantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunitiesCombined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol

      Nov 2Yahoo FinanceSUPN
      SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
      Nov 1Yahoo FinanceINDVSUPN
      Supernus (SUPN) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 30The Globe and MailSUPN
      Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Oct 30Yahoo FinanceSUPN
      Supernus Pharmaceuticals Inc (SUPN) Q3 2026 Earnings Call Highlights: Record Revenue, Raised ...
      Oct 30Yahoo FinanceSUPN
      Supernus Pharmaceuticals Q3 Earnings Call Highlights
      Oct 29Yahoo FinanceSUPN
      Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
      Oct 29Yahoo FinanceSUPN
      Supernus earnings missed by $0.21, revenue topped estimates
      Oct 29Investing.comSUPN
      Earnings call transcript: Supernus beats revenue in Q3 2026, misses EPS
      Oct 29Investing.comSUPN
      Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
      Oct 29BenzingaSUPN
      Supernus: Q3 Earnings Snapshot
      Oct 29Yahoo FinanceSUPN
      Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic
      Oct 29Yahoo FinanceSUPN
      Supernus Announces Third Quarter 2026 Financial Results
      Oct 29Yahoo FinanceSUPN
      Supernus under pressure as earnings test profitability ahead of merger
      Oct 29Investing.comSUPN
      Supernus Pharmaceuticals earnings: what to look for from SUPN
      Oct 28Yahoo FinanceSUPN
      Supernus Pharmaceuticals ends UBS credit line ahead of Indivior merger
      Oct 26Investing.comINDVSUPNUBS
      Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
      Oct 22Yahoo FinanceSUPN
      Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
      Oct 21Yahoo FinanceSUPN
      Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
      Oct 19Yahoo FinanceSUPN
      Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
      Oct 16Seeking AlphaSUPN
      Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
      Oct 14Investing.comSUPN
      Indivior, Supernus advance merger amid disclosure updates

      Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailINDVSUPN
      Why Did Supernus Pharmaceuticals (SUPN) Move Today?

      Supernus Pharmaceuticals (SUPN) is back in focus after reporting Q2 revenue of US$211.3 million, up 27.7% year on year, beating expectations and nudging full-year guidance higher on what management described as sustained product momentum. The upbeat quarter comes amid a more challenging period for Supernus Pharmaceuticals, with the share price down 15.1% year to date and about 13.5% lower over the past month, even though the 3-year total shareholder return of roughly 49% still points to a...

      Sep 19Yahoo FinanceSUPN
      How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook
      Sep 18Yahoo FinanceSUPN
      Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
      Sep 18BarchartSUPN
      Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

      Indivior Pharmaceuticals (INDV) said Thursday that its board of directors has declared a special cas

      Sep 17Yahoo FinanceINDVSUPN
      Supernus at Wells Fargo conference: growth after patent losses
      Sep 10Investing.comSUPNWFC
      Supernus at cantor global healthcare conference: merger and growth push
      Sep 9Investing.comSUPN
      Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD
      Sep 8Investing.comSUPN
      Supernus Pharmaceuticals to Participate in September Investor Conferences

      ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Wednesday, September 9, 2026Fireside chat: 2:45 p.m. ETPlace: Waldorf Astoria, New York, NYWebcast Link: Here Wells Fargo Hea

      Sep 2Yahoo FinanceSUPN
      Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
      Aug 31Yahoo FinanceSUPN
      Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

      Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a...

      Aug 28BarchartSUPN
      Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

      Investors need to pay close attention to SUPN stock based on the movements in the options market lately.

      Aug 24Yahoo FinanceSUPN
      Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

      INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

      Aug 21Yahoo FinanceSUPN

      This is the newest page. Registered accounts read further back.